- Home
- AVTE
AVTE
Aerovate Therapeutics Inc.
as 11-14-2024 10:31am EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $11.75 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $32.42 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aerovate Therapeutics Inc. News
AVTE Breaking Stock News: Dive into AVTE Ticker-Specific Updates for Smart Investing
BioPharma Dive
15 days ago
Jade, another biotech spinout of Paragon, to merge with Aerovate
GlobeNewswire
15 days ago
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
MT Newswires
4 months ago
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown
BioPharma Dive
4 months ago
Ligand to buy Apeiron; Roche reports another TIGIT setback
GlobeNewswire
4 months ago
Aerovate Therapeutics to Explore Strategic Alternatives
Clinical Trials Arena
4 months ago
Aerovate slashes workforce after failed Phase IIb trial
Zacks
5 months ago
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
MT Newswires
5 months ago
--Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy
Compare AVTE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTE Aerovate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.